Given the success of the CCL2 synthesis inhibitor bindarit in ameliorating several animal disease models and human clinical conditions associated with peripheral inflammatory disease, initial studies were conducted to examine its effects on elements critical to neuroinflammatory disease. This evidence concerns the gene CCL2 and glycogen storage disease VI.